A
Amy P. Abernethy
Researcher at Duke University
Publications - 586
Citations - 29463
Amy P. Abernethy is an academic researcher from Duke University. The author has contributed to research in topics: Palliative care & Population. The author has an hindex of 76, co-authored 586 publications receiving 25420 citations. Previous affiliations of Amy P. Abernethy include University of Technology, Sydney & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Treatment Patterns for Advanced Non–Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice
TL;DR: These findings show the diversity, short treatment duration, and lack of efficacy of second-line chemotherapy regimens for NSCLC in the community oncology setting.
Journal ArticleDOI
Utility and use of palliative care screening tools in routine oncology practice.
TL;DR: This article reviews frequently used and available screening instruments for common palliative needs in cancer patients and provides an example of a novel technology-based screening approach to quickly identify and address a critical patient concern.
Journal ArticleDOI
Collecting Data on Quality Is Feasible in Community-Based Palliative Care
Arif H. Kamal,Janet Bull,Charles S. Stinson,Debra Blue,Robert W. M. Smith,Rikki Hooper,Melanie Kelly,Judith Kinsella,Mark Philbrick,Agbessi Gblokpor,Jane L. Wheeler,William Downey,Amy P. Abernethy +12 more
TL;DR: Standardized data collection is feasible in routine community-based palliative care and is valuable for quality monitoring.
Journal ArticleDOI
How do non-physician clinicians respond to advanced cancer patients’ negative expressions of emotions?
Stewart C. Alexander,Stewart C. Alexander,Kathryn I. Pollak,Perri Morgan,Justine Strand,Amy P. Abernethy,Amy S. Jeffreys,Robert M. Arnold,Maren K. Olsen,Maren K. Olsen,Keri L. Rodriguez,Sarah K. Garrigues,Justin R.E. Manusov,James A. Tulsky,James A. Tulsky +14 more
TL;DR: A better understanding of NPC–patient interactions can contribute to improved communication training for NPCs and, ultimately, to higher quality patient care in cancer.
Journal ArticleDOI
A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial.
Sharon M. Weinstein,Sharon M. Weinstein,Amy P. Abernethy,Susan E. Spruill,Isadore M. Pike,Andrea True Kelly,Linda G. Jett +6 more
TL;DR: This proof-of-concept study for KRN5500 in patients with advanced cancer and any type of neuropathic pain found gastrointestinal adverse events to be the predominant safety concern and provided the first indication of clinical and statistical efficacy in reducing pain intensity.